IGFBP2 and metabolic dysfunction-associated steatotic liver disease: Our finding that DIO associates with decreased Igfbp2 expression (Figure 1(d)) and 5hmC loss (Figure 3(b)iii) builds on these data and supports the utility of this model for NAFLD studies.